Paolo Grumati | Cell Biology | Best Researcher Award

Prof. Paolo Grumati | Cell Biology | Best Researcher Award

Prof. Paolo Grumati,  TIGEM, Italy.

Dr. Paolo Grumati is a prominent researcher and academic with a focus on molecular biology, particularly the study of autophagy and its role in diseases such as muscular dystrophies and neurodegenerative disorders. His academic journey, beginning with a Master’s and Ph.D. from the University of Padova, laid the foundation for his pioneering work in the molecular mechanisms underlying disease pathogenesis. Dr. Grumati’s professional endeavors have included roles at esteemed institutions like Johann Wolfgang Goethe University and the Telethon Institute of Genetics and Medicine (TIGEM), where he leads groundbreaking research in selective autophagy. His work, which integrates advanced techniques like CRISPR/Cas9, has earned him widespread recognition and numerous accolades, including positions as Associate Professor at the University of Naples. His research has had a significant impact on the scientific community, particularly in the areas of cellular maintenance and therapeutic development.

Profile

Scopus

 

Early Academic Pursuits 🎓


Paolo Grumati’s academic journey began at the University of Padova in Italy, where he pursued a Master’s Degree in Medical Biotechnologies, graduating in 2005. His deep curiosity in the molecular underpinnings of human biology led him to continue his studies with a Ph.D. in Genetic and Molecular Biology, completed between 2006 and 2009. During his Ph.D., he focused on the genetic mechanisms that contribute to various diseases, a pursuit that sparked his lasting interest in molecular biology and disease pathogenesis. His early academic training laid a strong foundation for his future research in the biochemistry of diseases, especially those that affect muscle function and cellular processes.

Professional Endeavors 💼


Dr. Grumati’s professional career has been marked by an impressive trajectory across prestigious institutions. After completing his postdoctoral work on the pathogenesis of muscular dystrophies at the University of Padova, he moved to Germany, where he took a position at the Institute of Biochemistry II at Johann Wolfgang Goethe University. There, between 2013 and 2018, he specialized in the biochemistry and molecular biology of autophagy, a crucial cellular process related to health and disease. His expertise in autophagy became a defining element of his career, and in 2019, he was appointed as the Assistant Investigator and Head of the Mass Spectrometry Core at the Telethon Institute of Genetics and Medicine (TIGEM), where he leads innovative research into the molecular mechanisms of selective autophagy. Throughout these roles, Dr. Grumati has built a reputation for integrating advanced techniques like CRISPR/Cas9 into his work, influencing the field of genetic research.

Contributions and Research Focus 🔬


Dr. Grumati’s research focus has consistently revolved around the intricate molecular processes that govern cellular maintenance and disease, particularly through the lens of autophagy. Since becoming a principal investigator in 2019, his work at TIGEM has concentrated on understanding the molecular mechanisms of selective autophagy, which plays a pivotal role in cellular health and disease. He has pioneered methods to study and manipulate these processes, contributing significantly to the understanding of diseases such as muscular dystrophies and neurodegenerative disorders. His research not only delves into the underlying biology of these conditions but also seeks to identify therapeutic targets that could help manage or even cure these diseases.

Accolades and Recognition 🏆


Dr. Grumati has received widespread recognition for his work in molecular biology and biochemistry. His contributions to the field of autophagy and muscle biology have been honored with leadership roles in prominent research teams, including his time as Team Leader of the Frankfurt CRISPR/Cas9 Screening Center. His excellence in research has earned him a faculty position as Assistant Professor at the University of Naples “Federico II” and an eventual promotion to Associate Professor in 2024. His expertise in mass spectrometry and molecular biology has also made him a sought-after figure in the scientific community, where he is frequently invited to collaborate on interdisciplinary research projects.

Impact and Influence 🌍


Dr. Grumati’s research has had a lasting impact on the scientific community, particularly in the fields of autophagy and muscular dystrophies. His work has influenced both theoretical and applied aspects of molecular biology, from basic research to potential therapeutic interventions. Through his leadership at TIGEM and his involvement in international collaborations, Dr. Grumati has helped to shape the direction of research into autophagy-related diseases. His studies have not only provided insights into the cellular mechanisms at play in these diseases but also paved the way for future therapeutic strategies. He is seen as a key figure in the advancement of precision medicine and molecular therapeutics.

Legacy and Future Contributions 🔮

As Dr. Grumati moves forward in his career, his contributions to the fields of genetics and molecular biology are expected to have a profound and lasting influence. His current work, focusing on selective autophagy, holds promise for the development of novel treatments for diseases that currently have limited therapeutic options. His legacy will likely include innovations in understanding cellular degradation processes and their application to genetic disorders and other diseases. The future of Dr. Grumati’s research will continue to explore the molecular intricacies of human health, offering the potential for breakthroughs in regenerative medicine and disease treatment.

Teaching and Mentorship 👨‍🏫


Beyond his research, Dr. Grumati has made a significant impact through his academic roles at the University of Naples. As an Associate Professor, he plays a key role in shaping the next generation of molecular biologists. His teaching focuses on imparting knowledge in genetics, biochemistry, and molecular biology, with an emphasis on practical research applications. His mentorship has helped guide many students and early-career researchers, who have gone on to make their own contributions to the field. Dr. Grumati’s ability to translate complex scientific concepts into accessible lessons ensures that his influence extends far beyond his own research.

Publication

  • Title: Cortico-striatal circuit mechanisms drive the effects of D1 dopamine agonists on memory capacity in mice through cAMP/PKA signalling
    Authors: M. de Risi, D. Cavezza, G. Torromino, P. Grumati, E. de Leonibus
    Year: 2025

 

  • Title: Two FAM134B isoforms differentially regulate ER dynamics during myogenesis
    Authors: V. Buonomo, K.O. Lohachova, A. Reggio, R.M. Bhaskara, P. Grumati
    Year: 2025

 

  • Title: Ezrin defines TSC complex activation at endosomal compartments through EGFR-AKT signaling
    Authors: G. Giamundo, D. Intartaglia, E. del Prete, R. De Cegli, I. Conte
    Year: 2025

 

  • Title: 3D Rotary Wet-Spinning (RoWS) Biofabrication Directly Affects Proteomic Signature and Myogenic Maturation in Muscle Pericyte–Derived Human Myo-Substitute
    Authors: A. Reggio, C. Fuoco, F. de Paolis, M. Costantini, C. Gargioli
    Year: 2025

 

  • Title: Cross-Linking Mass Spectrometry to Capture Protein Network Dynamics of Cell Membranome
    Authors: L. Santorelli, M. Costanzo, S. Petrosino, M. Ruoppolo, P. Grumati
    Year: 2025

 

  • Title: Mitochondrial mechanotransduction through MIEF1 coordinates the nuclear response to forces
    Authors: P. Romani, G. Benedetti, M. Cusan, G. Martello, S. Dupont
    Year: 2024

 

Conclusion


Dr. Paolo Grumati’s career exemplifies the integration of scientific inquiry with practical application, as his research continues to shed light on crucial molecular processes that affect human health. His contributions to the understanding of autophagy have opened new avenues for potential therapeutic strategies in treating genetic disorders and other diseases. As he continues to lead research at TIGEM and teach at the University of Naples, Dr. Grumati’s legacy is set to influence the fields of molecular biology, genetics, and medicine for years to come. His work remains pivotal in advancing both the theoretical understanding of disease mechanisms and the development of new therapeutic approaches, positioning him as a key figure in modern biomedical research.

Shilin Luo | Neurogenetics and Molecular Neuroscience | Best Researcher Award

Prof. Shilin Luo | Neurogenetics and Molecular Neuroscience | Best Researcher Award

Prof. Shilin Luo, Xiangya Hospital, Central South University, China.

Dr. Shilin Luo is a leading expert in neuropharmacology and medicinal chemistry, with a strong academic background in traditional Chinese medicine and modern pharmacology. His research focuses on the pathogenesis of neurodegenerative diseases and the development of innovative drug therapies. Through his work at Xiangya Hospital, Central South University, and previous research at Emory University, he has made significant contributions to understanding neurological disorders. His studies on animal models and risk genes have paved the way for novel treatment strategies, earning him international recognition.

Profile

Scopus

Orcid

 

🎓 Early Academic Pursuits

Dr. Shilin Luo’s journey into the world of medical science began with a deep-rooted passion for understanding the complexities of neurological diseases. He earned his Bachelor’s degree in Chinese Materia Medica from Shenyang Pharmaceutical University, where he developed a strong foundation in traditional Chinese medicine and pharmacology. With an insatiable thirst for knowledge, he further pursued a Ph.D. in Medicinal Chemistry at China Pharmaceutical University, specializing in the research of active ingredients in natural products. Under the mentorship of Prof. Wencai Ye, a distinguished scholar, Dr. Luo honed his expertise in medicinal chemistry, paving the way for groundbreaking discoveries in neuropharmacology.

👨‍🎓 Professional Endeavors

To deepen his expertise, Dr. Luo embarked on postdoctoral research at Emory University’s School of Medicine in the Department of Pathology and Laboratory Medicine. Working under the esteemed Prof. Keqiang Ye, he focused on neurobiology and neuropharmacology, contributing significantly to the understanding of neurodegenerative diseases. His research provided novel insights into the molecular mechanisms underlying neurological disorders, positioning him as a leading figure in the field. He later took on a pivotal role as a professor in the Department of Neurology at Xiangya Hospital, Central South University, where he continues to mentor young scientists and advance medical research.

🧪 Contributions and Research Focus

Dr. Luo’s research is primarily dedicated to uncovering the pathogenesis of neurodegenerative diseases and developing therapeutic interventions. His work in animal models of pathogenic and risk genes for neurological disorders has been instrumental in identifying potential drug targets. By integrating traditional Chinese medicine with modern pharmacology, he has contributed to the development of innovative neuroprotective agents. His studies on the molecular mechanisms of neuronal degeneration have led to promising advancements in combating conditions such as Alzheimer’s and Parkinson’s disease.

🏆 Accolades and Recognition

Throughout his career, Dr. Luo has been widely recognized for his groundbreaking contributions to neuropharmacology. His research has been published in high-impact scientific journals, earning him international acclaim. His dedication to scientific excellence has garnered prestigious awards, and he is frequently invited to deliver keynote lectures at global conferences. His work continues to inspire fellow researchers, solidifying his reputation as a distinguished scientist in neurological drug development.

🏰 Impact and Influence

Dr. Luo’s impact extends beyond the laboratory, as he actively contributes to the medical community through mentorship and collaboration. His efforts in integrating traditional Chinese medicinal principles with cutting-edge pharmacological approaches have opened new avenues for drug discovery. His research findings have not only influenced academic discourse but have also laid the groundwork for potential clinical applications, bringing hope to patients suffering from neurodegenerative diseases.

⚛️ Legacy and Future Contributions

As a visionary scientist, Dr. Luo continues to push the boundaries of neurological research. His commitment to translational medicine aims to bridge the gap between laboratory discoveries and clinical applications. By fostering interdisciplinary collaborations and mentoring the next generation of researchers, he is shaping the future of neuropharmacology.

 

Publication

  • Disease-modifying therapies for Alzheimer’s disease: Clinical trial progress and opportunity
    Authors: Yujie Zhang, Jie Chen, Yanru Li, Bin Jiao, Shilin Luo
    Year: 2025

 

  • The role of the probiotic Akkermansia muciniphila in brain functions: insights underpinning therapeutic potential
    Authors: Ruiling Xu, Yuxuan Zhang, Shurui Chen, Yaohui Zeng, Xuan Fu, Ti Chen, Shilin Luo, Xiaojie Zhang
    Year: 2023

 

  • Nonviral delivery systems for antisense oligonucleotide therapeutics
    Authors: Si Huang, Xin-Yan Hao, Yong-Jiang Li, Jun‑Yong Wu, Da-Xiong Xiang, Shilin Luo
    Year: 2022

 

  • The Microglial membrane receptor TREM2 mediates exosome secretion to promote phagocytosis of amyloid‐β by microglia
    Authors: Si Huang, Xiaoli Liao, Junyong Wu, Xiaojie Zhang, Yamin Li, Daxiong Xiang, Shilin Luo
    Year: 2022

 

  • Correction: Microglial ERK-NRBP1-CREB-BDNF signaling in sustained antidepressant actions of (R)-ketamine
    Authors: Not explicitly listed
    Year: 2021

 

  • Polygonatum sibiricum Polysaccharides Protect against MPP‐Induced Neurotoxicity via the Akt/mTOR and Nrf2 Pathways
    Authors: Si Huang, Haiyan Yuan, Wenqun Li, Xinyi Liu, Xiaojie Zhang, Daxiong Xiang, Shilin Luo, Guodong Zhang
    Year: 2021

 

  • Bushen-Tiansui Formula Improves Cognitive Functions in an Aβ1–42 Fibril-Infused Rat Model of Alzheimer’s Disease
    Authors: Chenxia Sheng, Panpan Xu, Xinyi Liu, Weijun Peng, Daxiong Xiang, Shilin Luo
    Year: 2020

 

  • Osteogenesis activity of isocoumarin a through the activation of the PI3K-Akt/Erk cascade-activated BMP/RUNX2 signaling pathway
    Authors: Not explicitly listed
    Year: 2019

 

  • Akt Phosphorylates NQO1 and Triggers its Degradation, Abolishing Its Antioxidative Activities in Parkinson’s Disease
    Authors: Shilin Luo, Seong Su Kang, Zhi-Hao Wang, Xia Liu, Julia X Day, Zhiping Wu, Junmin Peng, Daxiong Xiang, Wolfdieter Springer, Keqiang Ye
    Year: 2019

 

  • Puerarin-loaded PEG-PE micelles with enhanced anti-apoptotic effect and better pharmacokinetic profile
    Authors: Not explicitly listed
    Year: 2018

 

Conclusion

Dr. Luo’s unwavering dedication to neurological research continues to shape the future of neuropharmacology. His innovative approach, combining traditional medicinal insights with modern scientific advancements, has the potential to revolutionize drug development for neurodegenerative diseases. As a mentor, researcher, and pioneer in his field, his contributions will leave a lasting impact on both academia and clinical medicine, offering hope for more effective treatments in the years to come.

 

Baoying Huang | Pathogen Biology | Best Researcher Award

Baoying Huang | Pathogen Biology | Best Researcher Award

Ms. Baoying Huang,  National Institute for Viral Disease Control and Prevention, China.

Dr. Baoying Huang, a distinguished professor at the Biotech Center for Viral Disease Emergency, China CDC, has over two decades of experience in combating viral diseases. Her expertise lies in vaccine and antiviral drug development for emerging and re-emerging infectious diseases, including COVID-19, monkeypox, and other human coronaviruses.

 

profile

Scopus

🎓 Education Experience

2008.09–2011.07: Doctor of Medicine, Pathogen Biology,Biotech Center for Viral Disease Emergency, China CDC.2005.09–2008.07: Master of Biology, Pathogen Biology,Biotech Center for Viral Disease Emergency, China CDC. 2001.09–2005.07: Bachelor of Biology,
Life Science Department, Nan Hua University, China.

👩‍🔬 Professional Experience

2020.07–Present:  Professor, China CD ,Focus: Vaccine and antiviral drug R&D for SARS-CoV-2 and poxvirus diseases, including COVID-19 and monkeypox. Key Role: Participated in COVID-19 Emergency Projects for SARS-CoV-2 variant monitoring in China.2015.07–2020.07:  Associate Professor, China CDC. Focus: Vaccine and antiviral drug R&D for emerging infectious diseases like influenza and coronaviruses (SARS-CoV, MERS-CoV).2015.04–2015.06:  Assistant Professor, China CDC. Global Health Support Program: Worked in Sierra Leone to establish Ebola lab systems, improving public health infrastructure.2011.07–2015.07: Assistant Professor, China CDC. Focus: Pathogenic molecular mechanisms of influenza viruses, pseudo-virus applications, and gene-engineered vaccines. 2005.09–2011.07:  Graduate Researcher, IVDC, China CDC. Specialization: Developing universal influenza vaccines for cross-protection against various strains.

🔬 Research Focus

Baoying Huang’s work is dedicated to:Vaccine Development: COVID-19 vaccines (BBIBP-CorV, mRNA vaccines) and pan-orthopoxvirus solutions.Emerging Diseases: Countermeasures for SARS-CoV-2, monkeypox, and other viral threats.Diagnostics: Whole-genome sequencing and real-time PCR for virus detection and monitoring.Therapeutics: Screening novel antivirals targeting viruses like SARS-CoV-2 and monkeypox.Key achievements include:Leading the development of Sinopharm COVID-19 vaccine, later approved by WHO for Emergency Use Listing.Establishing monitoring systems for SARS-CoV-2 variants and assessing their impact on public health measures. Advancing monkeypox vaccine research and identifying promising antiviral compounds against orthopoxviruses.

📚 Publications

  • Title: Molecular architecture of monkeypox mature virus
    • Authors: Hong, Y., Huang, B., Zhang, J., Tan, W., Li, S.
    • Year: 2024

 

  • Title: Vaccinia virus Tiantan strain blocks host antiviral innate immunity and programmed cell death by disrupting gene expression
    • Authors: Wu, C., Zhang, Z., Li, Z., Deng, Y., Tan, W.
    • Year: 2024

 

  • Title: A clinically used anti-human papilloma virus agent (3-hydroxyphthalic anhydride-modified bovine β-lactoglobulin) has a potential for topical application to prevent sexual transmission of monkeypox virus
    • Authors: Sha, Y., Huang, B., Hua, C., Tan, W., Jiang, S.
    • Year: 2024

 

  • Title: Development of a multiplex real-time PCR assay for the simultaneous detection of mpox virus and orthopoxvirus infections
    • Authors: Fan, Z., Xie, Y., Huang, B., Tan, W., Guo, F.
    • Year: 2024

 

  • Title: Accurate determination of the whole genome sequencing and open reading frames composition of non-replicating Tiantan strain of vaccinia virus based on novel long read sequencing platform
    • Authors: Zhang, Z., Wu, C., Li, H., Huang, B., Tan, W.
    • Year: 2024

 

  • Title: Characterization of whole genomes from recently emerging Mpox cases in several regions of China, 2023
    • Authors: Wu, C., Cui, L., Pan, Y., Wang, Q., Tan, W.
    • Year: 2024

 

  • Title: Intranasal immunization with single-dose vaccine based on recombinant influenza virus H1N1 expressing the extracellular domain of respiratory syncytial virus G protein induces robust immunity and protection in mice
    • Authors: Han, R., Wang, D., Wang, T., Huang, B., Tan, W.
    • Year: 2024

 

  • Title: Rapid identification of full-length genome and tracing variations of monkeypox virus in clinical specimens based on mNGS and amplicon sequencing
    • Authors: Wu, C., A, R., Ye, S., Lu, J., Tan, W.
    • Year: 2024

 

  • Title: Long-lasting humoral and cellular memory immunity to vaccinia virus Tiantan provides pre-existing immunity against mpox virus in Chinese population
    • Authors: Li, M., Guo, Y., Deng, Y., Gao, G.F., Liu, J.
    • Year: 2024

 

  • Title: Identification of the VP37 pocket of monkeypox virus as a promising target for pan-orthopoxvirus inhibitors through virtual screening and antiviral assays
    • Authors: Huo, S., Wu, L., Huang, B., Xu, Z., Tan, W.
    • Year: 2024

 

Conclusion

Dr. Huang’s career exemplifies unwavering dedication to improving public health through innovation in vaccine development, antiviral research, and diagnostic technologies. Her contributions to tackling global health challenges, such as the COVID-19 pandemic and monkeypox outbreaks, have significantly impacted infectious disease prevention and control worldwide. As viruses continue to evolve, her pioneering work remains a cornerstone in safeguarding global health.